Dalian BIO-CHEM Company Limited Stocks

CN¥ 26.69Last Updated 03.04.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 2.70B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 26.69
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dalian BIO-CHEM Company Limited produces and sells bactericides, antiseptics, and fungicides for various industrial applications in Europe, North and South Americas, the Middle East, Africa, and Asia. The company's products are used as disinfection; algaecide in water treatment, such as petrochemicals, electricity, central air conditioning, and industrial cooling water; anti-corrosion in emulsions, mineral slurries, pigment dispersions, adhesives, tackifiers, metalworking fluids, and cosmetics aqueous system; and aqueous system of leather, paint and coating, textile, and dyeing. Its products also used for anti-mildew and anti-algae applications, as well as manufactures dry film preservative, which is used for paints and coatings. Dalian BIO-CHEM Company Limited was founded in 2003 and is based in Dalian, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks